FindTrial
Sign In

PD 0332991

DRUG7 trials

Sponsors

Pfizer, Weill Medical College of Cornell University, University of California, San Francisco, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Institut Bergonié

Conditions

Advanced Gastrointestinal Stromal TumorsAnaplastic AstrocytomaBreast CancerCarcinoma, Squamous Cell of Head and NeckGlioblastomaGliosarcomaHigh-Risk MyelodysplasiaMantle Cell Lymphoma

Phase 1

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
TerminatedNCT01111188
Weill Medical College of Cornell UniversityMantle Cell Lymphoma
Start: 2010-08-23End: 2019-04-12Updated: 2019-06-27
A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia
TerminatedNCT01701375
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsHigh-Risk Myelodysplasia, Refractory Acute Leukemia, Relapsed Acute Leukemia
Start: 2012-09-30End: 2013-04-30Updated: 2013-09-09
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
CompletedNCT02101034
Washington University School of MedicineCarcinoma, Squamous Cell of Head and Neck
Start: 2014-06-17End: 2023-11-10Updated: 2023-12-21

Phase 2

An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
CompletedNCT00555906
PfizerMultiple Myeloma
Start: 2008-01-31End: 2013-03-31Updated: 2015-03-19
Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
CompletedNCT00721409
PfizerBreast Cancer
Start: 2008-09-15End: 2017-12-20Updated: 2019-11-04
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
TerminatedNCT01227434
University of California, San FranciscoAnaplastic Astrocytoma, Glioblastoma, Gliosarcoma
Start: 2010-09-30End: 2013-12-31Updated: 2015-07-17
Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
CompletedNCT01907607
Institut BergoniéAdvanced Gastrointestinal Stromal Tumors
Start: 2014-02-28End: 2019-02-28Updated: 2025-08-24

Related Papers

Abstract P1-18-13: Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC) participating in the PALOMA trials
Cancer Research2022-02-151 citations
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
2020-07-18127 citations
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
2020-03-1230 citations
Abstract P1-19-16: Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2–negative advanced breast cancer: An updated analysis
Cancer Research2020-02-151 citations
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
2019-07-2492 citations
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma
Leukemia & lymphoma/Leukemia and lymphoma2019-05-2325 citations
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
2018-10-1945 citations
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
2018-07-2565 citations
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
JNCI Journal of the National Cancer Institute2018-06-2091 citations
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
2018-06-0170 citations
Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4/6 inhibitor, and cetuximab in platinum-resistant HPV unrelated (-) recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).
Journal of Clinical Oncology2018-05-2017 citations
Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2‒) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.
Journal of Clinical Oncology2018-05-201 citations
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).
Journal of Clinical Oncology2017-05-2067 citations
Abstract 2840: CDK4/6 inhibitor PD-0332991 (palbociclib) promotes cell death and synergizes with CPT-11 in colorectal cancer under hypoxia <i>in vitro</i>
Cancer Research2016-07-15
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment
Current Medical Research and Opinion2016-02-2019 citations
Abstract P4-13-02: Treatment patterns of post-disease progression in the PALOMA-1/TRIO-18 trial
Cancer Research2016-02-155 citations
Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18).
Journal of Clinical Oncology2015-05-206 citations
A phase I trial of the addition of the CDK 4/6 inhibitor palbociclib to cetuximab in patients with incurable head and neck squamous cell carcinoma (HNSCC).
Journal of Clinical Oncology2015-05-205 citations
Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged ≥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial.
Journal of Clinical Oncology2015-05-204 citations
The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/ HER2- metastatic breast cancer (MBC): Subanalysis from a randomized phase II study.
Journal of Clinical Oncology2015-05-203 citations

2 more papers not shown